UCB SA (0NZT.IL)

124,55 -0,25 (-0,20%) In data: 05:36PM BST. Mercato aperto.

UCB SA

AllEe de la Recherche, 60
Brussels 1070
Belgium
32 2 559 99 99
https://www.ucb.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 8.600

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Jean-Christophe Tellier	CEO & Exec. Director	3,34M	N/D	1959
Ms. Sandrine Dufour CFA	Exec. VP & CFO & Chief Corp. Devel.	N/D	N/D	1966
Ms. Kirsten Lund-Jurgensen	Exec. VP of Supply & Technology Solutions	N/D	N/D	1959
Dr. Dhavalkumar D. Patel M.D., Ph.D.	Exec. VP & Chief Scientific Officer	N/D	N/D	1961
Mr. Jean-Luc Fleurial	Exec. VP & Chief HR Officer	N/D	N/D	1965
Prof. Iris Low-Friedrich	Exec. VP, Chief Medical Officer and Head of Devel. & Medical Patient Value Practices	N/D	N/D	1960
Mr. Emmanuel Caeymaex	Exec. VP of Immunology Solutions & Head of US	N/D	N/D	1969
Ms. Caroline Vancoillie	Chief Accounting Officer, Head of Group Fin. & CFO of Patient Value Functions	N/D	N/D	N/D
Antje Witte	Head of Investor Relations	N/D	N/D	N/D
Ms. Denelle J. Waynick Johnson J.D.	Exec. VP & Gen. Counsel	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Governance aziendale

L'ISS Governance QualityScore di UCB SA al 1 ottobre 2023 è 3. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 4; diritti degli azionisti: 1; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.